Review of 10 clinical trials supports CBD effectiveness for Dravet syndrome in children
A narrative review of 10 clinical trials found CBD (Epidiolex) effective in reducing seizure frequency in pediatric Dravet syndrome patients, with manageable side effects and important drug interactions.
Quick Facts
What This Study Found
Across 10 clinical trials, CBD demonstrated efficacy in reducing seizure frequency in children with Dravet syndrome. Common adverse events included somnolence, diarrhea, and decreased appetite. Interactions with clobazam were clinically significant.
Key Numbers
10 clinical trials reviewed. CBD reduced seizure frequency in Dravet syndrome. Common side effects: somnolence, diarrhea, decreased appetite. Clobazam interaction significant.
How They Did This
Narrative review of 10 clinical trials evaluating CBD efficacy and safety in pediatric Dravet syndrome patients.
Why This Research Matters
Dravet syndrome is among the most severe childhood epilepsies with limited treatment options. CBD (Epidiolex) was the first cannabis-derived drug approved for this condition, and this review consolidates the clinical evidence.
The Bigger Picture
The FDA approval of Epidiolex for Dravet syndrome was a landmark for cannabinoid medicine. This review confirms the evidence base supporting that decision and highlights ongoing safety considerations.
What This Study Doesn't Tell Us
Narrative review without systematic methodology or quantitative synthesis. Most trials used specific pharmaceutical-grade CBD (Epidiolex) at defined doses, which may not generalize to other CBD products. Focus on Dravet syndrome only.
Questions This Raises
- ?Is CBD effective long-term beyond the trial durations studied?
- ?Should the clobazam-CBD interaction be leveraged therapeutically or minimized?
Trust & Context
- Key Stat:
- 10 clinical trials support CBD efficacy in pediatric Dravet syndrome
- Evidence Grade:
- Narrative review of clinical trials including RCTs. Provides useful summary but without quantitative synthesis.
- Study Age:
- Published 2023.
- Original Title:
- The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.
- Published In:
- European journal of medical research, 29(1), 182 (2024)
- Authors:
- Aderinto, Nicholas, Olatunji, Gbolahan, Kokori, Emmanuel, Ajayi, Yusuf Ismaila, Akinmoju, Olumide, Ayedun, Abiola Samuel, Ayoola, Oluwapelumi Ikeoluwa, Aderinto, Noah Oluwaseun
- Database ID:
- RTHC-05062
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does CBD work for Dravet syndrome?
Yes. This review of 10 clinical trials confirms that pharmaceutical CBD (Epidiolex) reduces seizure frequency in children with Dravet syndrome. The evidence supported FDA approval for this indication. Side effects are generally manageable but require monitoring.
What are the side effects of CBD in Dravet syndrome?
The most common side effects across trials were somnolence (sleepiness), diarrhea, and decreased appetite. The interaction between CBD and clobazam (a commonly co-prescribed seizure medication) is clinically important, as it can increase both efficacy and side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05062APA
Aderinto, Nicholas; Olatunji, Gbolahan; Kokori, Emmanuel; Ajayi, Yusuf Ismaila; Akinmoju, Olumide; Ayedun, Abiola Samuel; Ayoola, Oluwapelumi Ikeoluwa; Aderinto, Noah Oluwaseun. (2024). The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.. European journal of medical research, 29(1), 182. https://doi.org/10.1186/s40001-024-01788-6
MLA
Aderinto, Nicholas, et al. "The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials.." European journal of medical research, 2024. https://doi.org/10.1186/s40001-024-01788-6
RethinkTHC
RethinkTHC Research Database. "The efficacy and safety of cannabidiol (CBD) in pediatric pa..." RTHC-05062. Retrieved from https://rethinkthc.com/research/aderinto-2024-the-efficacy-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.